Head-to-head
BPC-157 vs KPV
Side by side from the same data: half-life, evidence tier, research amounts, common schedule, and every decay curve on one chart.
How they differ
A plain-language read of what actually sets them apart. Reference only, not medical advice.
Both are small recovery peptides looked at for the gut, and both clear quickly. KPV is a tiny three-piece fragment aimed at calming inflammation; BPC-157 is a longer peptide aimed at repair. Neither has a human dosing trial — the evidence is animal and lab studies.
Side by side
Every figure is drawn from this site's own compound data — the same numbers on each compound's page.
| Measure | BPC-157 | KPV |
|---|---|---|
| Category | Recovery | Recovery |
| Evidence | C · Animal or lab only | C · Animal or lab only |
| Route | Injectable | Injectable |
| Half-life | 4 h | 0.5 h |
| Typical vial | 5 / 10 mg | 5 / 10 / 20 mg |
| Research amount | 200–500 mcg | 200–500 mcg |
| Common schedule | Every day | Every day |
| Cycle / break | 4–6 / 2–4 | — |
| Studied for | Repair and recovery | Repair and recovery |
These amounts and schedules are figures discussed in research and community reports, shared for learning — not a recommendation and not medical advice. A step-by-step dosing schedule exists only where a human trial backs it; the evidence tier tells you which.
Decay curves, overlaid
Every compound on one chart — something the single-compound pages cannot show.
Each line is scaled to that compound's own first dose, so the chart shows how each one builds up over time — not how the compounds' doses compare to one another, which these different molecules share no common unit for.